BioCentury
ARTICLE | Clinical News

Impracor: Phase III start

July 29, 2013 7:00 AM UTC

This quarter, Imprimis will begin a double-blind, placebo-controlled, U.S. Phase III trial to evaluate Impracor for 14 days in about 350 patients. Imprimis is developing Impracor under section 505(b)(...